Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: Final report of a phase II trial

British Journal of Haematology

Volumn 96, Issue 2, 1997, Pages 328-332

  Younes, Anas ^a   Ayoub, Jean Pierre ^a   Sarris, Andreas ^a   Hagemeister, Frederick ^a   North, Lucille ^a   Pate, Odeal ^a   Mclaughlin, Peter ^a   Rodriguez, M Alma ^a   Romaguera, Jorge ^a   Kurzrock, Razelle ^a   Preti, Alejandro ^a   Bachier, Carlos ^a   Smith, Terry ^a   Cabanillas, Fernando ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

lymphoma; paclitaxel; taxol

Indexed keywords

CIMETIDINE; CISPLATIN; CYTARABINE; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL;

ADULT; AGED; ALOPECIA; ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MYALGIA; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 8044242947     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1997.d01-2012.x     Document Type: Article

References (9)

1. Armitage, J.O. (1995) Treatment of non-Hodgkin's lymphoma. New England Journal of Medicine, 328, 1023-1030.
2. Rodriguez, M.A., Cabanillas, F.C., Velasquez, W., Hagemeister, F.B., McLaughlin, P., Swan, F. & Romagucra, J.E. (1995) Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. Journal of Clinical Oncology, 13, 1734-1741.
3. Rowinsky, E.K. & Donehower, R.C. (1995) Paclitaxel (taxol). New England Journal of Medicine, 332, 1004-1014 (erratum: 333, 75).
4. Seidman. A.D., Hochhauser, D., Yao, T.J., Edelman, B.. Gollub, M., Hudis, C., O'Donoghue, M., Francis, P., Gilewski, T., Fennelly, D., Moynahan, M.E., Currie, V., Tao, Y., Leung, P., Berkery, R., Lin, S., Tong, W., Spriggs, D. & Norton, L. (1996) Ninty-six-hour paclitaxel infusion after progression during short taxene exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. Journal of Clinical Oncology, 14, 1877-1884.
5. Velasquez, W., Hagemeister, F., McLaughlin, P., Swan, F. Rodriguez, M., Romaguera, J. & Cabanillas, F. (1992) E-SHAP: an effective treatment for refractory and relapsing lymphoma. Proceedings of the American Society for Clinical Oncology, 11, 1111a.
6. Wilson, W.H., Berg, S.L., Bryant, G., Wittes, R.E., Bates, S., Fojo, A., Steinberg, S.M., Goldspiel, B.R., Herdt, J., O'Shaughnessy, J., Balis, P.M. & Chabner, B.A. (1994) Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. Journal of Clinical Oncology, 12, 1621-1629.
7. Wilson, W.H., Chabner, B.A., Bryant, G., Bates, S., Fojo, A., Regis, J., Jaffe, E., Steinberg, S.M., Goldspiel, B.R., Cheson, B. & Wittes, R.E. (1995) Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. Journal of Clinical Oncology, 13, 381-386.
8. Younes, A., Ayoub, J.P., Hagemeister, F.B., McLaughlin, P., Sarris, A., Rodriguez, M.A., Swan, F., Romaguera, J.E., Martin, J. & Cabanillas, F. (1996) No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule. Journal of Clinical Oncology, 14, 543-547.
9. Younes, A., Sarris, A., Melnyk, A., Romaguera, J., McLaughlin, P., Swan, F., Rodriguez, M.A., Hagemeister, F., Moore, D., North, L. & Cabanillas, F. (1995) Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma. Journal of Clinical Oncology, 13, 583-587.